In this situation, they may benefit from a pancreas-after-kidney transplant, but would it be reasonable to offer a “preemptive” SPKT to this population, preempting their requirement for insulin, just as we offer kidneys preemptively in patients with CKD prior to dialysis? This evidence concerns the gene INS and chronic kidney disease.